BioSpace’s Post

Systematic review on Role of GCSF in the treatment of cirrhosis of liver

Have you explored our new Challenge with Angelini Pharma? This new Open Innovation opportunity to identify new innovative Drug Delivery Systems (DDS) and Treatment Approaches will help to significantly improve the lives of people with epilepsy. Check out this post from Rafal Kaminski and learn more details about this Challenge: https://bit.ly/3XIET9Y #OpenInnovation #WazokuCrowd #epilepsy #angelinipharma #everystepcloser #withyouinmind

I am reaching out to share some exciting news! Recently, I completed a comprehensive systematic review on the role of Granulocyte Colony Stimulating Factor (G-CSF) in the treatment of liver cirrhosis. In this review, I delved into the existing literature to provide a thorough analysis of the efficacy and potential impact of G-CSF in managing liver cirrhosis. The findings are not only insightful but also hold promise for advancing our understanding of treatment options in this critical area. https://lnkd.in/gF5r4TQT #gcsf #systematicreview #livercirrhosis #cirrhosis #treatment #medical #pharma #research #researchpaper #followformore

Multiple GLP-1-based therapies for type 2 #diabetes and #obesity have been approved in recent years, reflecting their clinical effectiveness and immense potential to address the needs of large patient populations with #metabolic disorders. In an opportunity-rich but increasingly saturated market, success will hinge largely upon: 1) the ability to deliver clear efficacy and safety advantages over existing GLP-1 drugs; and 2) shortening time-to-market. See how the high throughput discovery #metabolomics workflow and population-scale #multiomics data provided by Sapient can deliver novel biological insights to speed development and differentiate the market positioning of new GLP-1 therapies: https://bit.ly/3QtzdMN #GLP1 #GLP1agonists #GLP1therapies

Multiple GLP-1-based therapies for type 2 #diabetes and #obesity have been approved in recent years, reflecting their clinical effectiveness and immense potential to address the needs of large patient populations with #metabolic disorders. In an opportunity-rich but increasingly saturated market, success will hinge largely upon: 1) the ability to deliver clear efficacy and safety advantages over existing GLP-1 drugs; and 2) shortening time-to-market. See how the high throughput discovery #metabolomics workflow and population-scale #multiomics data provided by Sapient can deliver novel biological insights to speed development and differentiate the market positioning of new GLP-1 therapies: https://bit.ly/4biCtlP #GLP1 #GLP1agonists #GLP1therapies

#Precision_Medicine Market Projected to Grow with magnificent CAGR During the 2023-2032 >> https://lnkd.in/ggYMzwHC #Precision #medicine is based on a unique concept that defines, two people infected with the same #disease don't need to have the same #physical response toward the #disorder. However, it depends on the surrounding environment and the influence of #genes and symptoms of the #patient. ROCHE LEON HOLDINGS, Illumina, Thermo Fisher Scientific, QIAGEN, Quest Diagnostics, Laboratory Corporation of America Holdings, Novartis, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company #precisionmedicine #precisionengineering #precisionperformance #precisionfarming #precisione #medicine #medicinehat #medicines #medicinestudent #healthcare #health #healthandwellness

#ALS is a devastating disease that steals the ability to move, speak, and breathe, with a life expectancy of just 2-5 years after diagnosis. The Accelerating Medicines Partnership (AMP®) in ALS aims to be a game-changer for both ALS treatment development and diagnostic tools.  Click here to watch the full video and learn more about this initiative. fnih.org/ampals The National Institutes of Health's National Institute of Neurological Disorders and Stroke (NINDS), FDA, AbbVie, The ALS Association, ALS TDI, ALS United Mid-Atlantic, Answer ALS, The Association for Frontotemporal Degeneration (AFTD), Biogen, Critical Path Institute (C-Path), EMD Serono, Inc., GSK, Eli Lilly and Company, Mitsubishi Tanabe Pharma America, QurAlis, and Target ALS, the FNIH announces the launch of the Accelerating Medicines #BridgestoBreakthroughs #MND #MotorNeuronDisease #AmyotrophicLateralSclerosis #AMPALS

🚶♀️Patients with Rheumatoid Arthritis (RA) struggle on the daily with chronic inflammation of the joints, along with weakness, fatigue, and unintentional weight loss. 📈 The IDEA-FAST Clinical Observation Study is aiming to monitor up to 200 RA patients through cutting-edge digital wearables and comprehensive questionnaires. We shortly explore the hallmarks of RA and the efforts of IDEA-FAST. Learn more about our project's endeavors at idea-fast.eu Innovative Health Initiative (IHI) EFPIA - European Federation of Pharmaceutical Industries and Associations #neurodegenerativediseases #sleepandfatigue #systemiclupuserythematosus

Patient Access is changing - Eli Lilly has announced direct to consumer access for through LillyDirect. For Plan Sponsors this is a time when education and employee experience remains challenging. As the U.S. Economy continues on a turbulent path, employers still face increased pressure from the employee benefits expense line, expensive treatments will continue to rise including new and emerging cell and gene therapies, GLP-1's and specialty drugs will outpace their usual significant increase on total claims. The GLP-1 Market is set to value at $71B by 2032* (JP Morgan market projection). The USI pharmacy team helps clients evaluate and implement various solutions to control the impact of prescriptions drugs on health plan spending.

H.C Weinwright analyst: #CardiolRx Poised for the Final Stretch; Initiating With a Buy Rating and $9 PT (1) CardiolRx is a Phase 2 stage, pharmaceutical-grade, proprietary cannabidiol oral solution in development as a treatment for recurrent #pericarditis (RP) and acute #myocarditis (AM); (2) Cardiol’s use of a deliberate, scientific evidence-based approach to CardiolRx clinical advancement creates a significant barrier to entry; and (3) CardiolRx targets RP and AM, heart disease indications with significant unmet medical need with high potential to make CardiolRx a blockbuster drug that we forecast could achieve >$1.3B in peak annual sales. #CRDL #Cardiol #HeartDisease #CVD